Lilly bets up to $3.8B on psychedelic nasal spray for treatment‑resistant depression
Eli Lilly will acquire AtaiBeckley for $2.8 billion upfront and up to $1 billion in milestones, gaining BPL‑003, a late‑stage psychedelic nasal spray for treatment‑resistant depression. Analysts project the drug could generate $1‑2 billion in sales, underscoring pharma’s rush into psychedelic therapeutics.